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Abstract
We evaluated an EPID‐based in‐vivo dosimetry (IVD) method for the dose verifica-
tion and the treatment reproducibility of lung SBRT‐VMAT treatments in clinical
routine. Ten patients with lung metastases treated with Elekta VMAT technique
were enrolled. All patients were irradiated in five consecutive fractions, with total
doses of 50 Gy. Set‐up was carried out with the Elekta stereotactic body frame.
Eight patients were simulated and treated using the Active Breath Control (ABC)
system, a spirometer enabling patients to maintain a breath‐hold at a predetermined
lung volume. Two patients were simulated and treated in free‐breathing using an
abdominal compressor. IVD was performed using the SOFTDISO software. IVD
tests were evaluated by means of (a) ratio R between daily in‐vivo isocenter dose
and planned dose and (b) γ‐analysis between EPID integral portal images in terms of
percentage of points with γ‐value smaller than one (γ%) and mean γ‐values (γmean)
using a 3%(global)/3 mm criteria. Alert criteria of ±5% for R ratio, γ% < 90%, and
γmean > 0.67 were chosen. 50 transit EPID images were acquired. For the patients
treated with ABC spirometer, the results reported a high level of accuracy in dose
delivery with 100% of tests within ±5%. The γ‐analysis showed a mean value of
γmean equal to 0.21 (range: 0.04–0.56) and a mean γ% equal to 96.9 (range: 78–100).
Relevant discrepancies were observed only for the two patients treated without
ABC, mainly due to a blurring dose effect due to residual respiratory motion. Our
method provided a fast and accurate procedure in clinical routine for verifying deliv-
ered dose as well as for detecting errors.
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1 | INTRODUCTION
The technological advancements in immobilization and imaging,
together with the ability to deliver high conformal doses and to
account for organ motion have led to a widespread implementation
of stereotactic body radiotherapy (SBRT) in a number of clinical set-
tings.1 Over the last few years, different new techniques including
volumetric modulated arc therapy (VMAT) have been successfully
applied to SBRT treatments, owing to high‐dose conformity,
improved sparing of healthy tissues and fast delivery time.2–5 In
SBRT treatments effective tumor motion control must be considered
much more compelling because reduced margins are needed to avoid
the irradiation of a large amount of normal tissue to high doses. Var-
ious methods have been developed to explicitly account for respira-
tion motion in SBRT treatments, as respiratory gating techniques,
breath‐hold techniques, and forced shallow breathing techniques.6 In
particular, Active Breath Control (ABC) methods by means of spirom-
eters have been used to actively hold the patient's breath at a cer-
tain level (e.g., at moderate deep inhalation) during the beam‐on
time, providing an accurate method to improve the localization of
lung and liver tumors during SBRT delivery.7,8 This strategy has been
recently implemented for SBRT treatments of extracranial metas-
tases, with the aim to increase the accuracy of treatment delivery
and the intrafraction treatment reproducibility.
The integration of several complex techniques such as SBRT,
VMAT, and breath‐hold into a single therapeutic strategy requires a
high‐level of confidence in the accuracy of the entire treatment
delivery process. The impact of treatment delivery errors represents
a major concern for these complex techniques, suggesting a strong
argument in favor of in‐vivo dosimetry (IVD).9 In particular, due to
very large dose over a few number of fractions used in SBRT treat-
ments, any error in treatment delivery can be much more detrimen-
tal as compared to conventional fractionated therapy, with a major
risk of completely nullify the curative intent or produce serious dam-
age to the patient. Among the different available dosimetric systems,
amorphous silicon electronic portal imaging devices (aSi‐EPID) have
demonstrated unique favorable characteristics for IVD purposes
(high two‐dimensional resolution and fast image acquisition) and sev-
eral algorithms were developed to reconstruct the dose within the
patient in terms of point dose, 2D‐dose distribution or 3D dose
distribution.10
At our institution, we developed a generalized procedure for the
daily in‐vivo isocenter dose reconstruction of radiation treat-
ments,11–15 leading to the foundation of an Italian national project
financed by the Istituto Nazionale di Fisica Nucleare16 and to the
development of the SOFTDISO software (Best Medical Italy, Italy).
The analysed results for conformal radiotherapy reported clinically
relevant differences between planned and delivered dose, detecting
the presence of dose discrepancies in more than 10% of the tests
with respect to our tolerance levels.17 Recent publications have
investigated the new challenges of epid‐based IVD for more complex
treatments as IMRT or VMAT, showing the feasibility and the sensi-
tivity of this approach to detect dose discrepancies also for these
complex techniques.18–20 By routine clinical use of EPID‐based IVD,
major dosimetric discrepancies due to anatomical variations21 and
serious errors including plan transfer errors due to record‐and‐verify
network failure were detected.22 A large clinical experience has been
recently carried out at the Radiotherapy Centre of the Fondazione
Policlinico Universitario A. Gemelli in Rome by means of an auto-
mated Epid‐based IVD procedure for more than 800 patients. The
application of IVD procedure has allowed the authors to detect on
average 6% of VMAT plans and 21% of 3D‐CRT plans outside at
least one of their tolerance levels.23
Experiences with Epid‐based IVD for SBRT treatments are even
more rare, with very few publications showing the technical feasibil-
ity of this strategy. McCowan et al. have recently validated an in‐
house physics‐based model which utilizes EPID images to recon-
struct the dose in patient during SBRT‐VMAT treatments.24 The
authors reported satisfactory results for lung and spine cases, with
pass rates better than 93% with 3%‐3 mm γ‐index tolerance level,
showing the suitability of this approach for clinical implementation.
Recently, a review by McCurdy and McCowan25 presented the tech-
nical aspects of in vivo dosimetry for lung SBRT, with a special
emphasis on Epid‐based IVD as a powerful tool to identify errors
that would have been missed with other common quality assurance
systems. The application of in vivo dosimetry to lung SBRT presents
new challenges with respect to other anatomical sites. These were
mainly due to the presence of low density tissues surrounding the
tumor, then straining the scatter estimation due to the loss of elec-
tronic equilibrium, and to the accuracy of the treatment planning
system algorithm to properly calculate the patient dose. Two recent
studies26,27 have investigated the effectiveness of epid‐based IVD
systems in detecting deliberately introduced errors during VMAT.
Although both studies had an exiguous number of patients in the
SBRT setting, they showed the ability of epid‐based IVD to detect
serious errors in dose delivery, anatomical variations of patients or
wrong set‐up.
We have recently applied our IVD algorithm, widely used for 3D‐
conformal, IMRT and VMAT, to lung SBRT treatments, with the aim
to supply, in quasi real‐time, both the isocenter dose and the γ‐analy-
sis of transit EPID images. In this paper, we presented our current
experience on real patients with EPID‐based IVD for the dose verifi-
cation of lung SBRT treatments delivered with breath‐hold multiseg-
mented VMAT technique.
2 | MATERIAL AND METHODS
2.A | Simulation, active breath control and
treatment planning
Ten patients with lung metastases treated with Elekta VMAT were
enrolled. Patients set‐up was carried out with the stereotactic
body frame (SBF, Elekta, Crawley, UK), an immobilization device
used to define target position by a stereotactic coordinates system
instead of anatomical landmarks or skin markers,28 with an
attached “vacuum pillow” customized to each patient. For eight of
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the ten enrolled patients, the breathing control was performed
using the ABC system (Elekta, Crawley, UK), a spirometer able to
immobilize the respiratory motion repeatedly and reproducibly for
a period of time that can be comfortably tolerated by the
patient.7,8
Before final CT acquisition for planning, patients underwent a
3‐day training to assess their comfort and compliance, the lung
capacity and the optimal breath hold length/level.
At the end, all patients underwent a moderate deep inspiration
breath‐hold at 75% to 80% of maximum inspiration capacity, and a
breath‐hold length of 20–30 s. During this training, three CT scan
studies were acquired in order to evaluate the interfraction repro-
ducibility of tumor position.
Two patients were not compliant to perform deep inspiration
breath‐hold using the ABC system due to their small lung tidal vol-
ume. For these two patients a forced shallow breathing was per-
formed by means of an abdominal plate compressor, with the aim to
reduce the diaphragmatic excursions while still permitting limited
normal respiration.
The clinical target volume was defined as the gross tumor vol-
ume. The planning target volume (PTV) was individually defined
for each patient based on Internal Margin (IM) and Setup Margin
(SM) assessment. The IM was defined based on the residual respi-
ratory excursions; the SM margin was set at 3 mm for all
patients.
Dose prescription was 50 Gy in five fractions for all patients.
VMAT plans were generated with Ergo++ treatment planning sys-
tem (TPS) (Elekta, Crawley, England). This is an anatomy‐based TPS
that supplies a simplified approach to create VMAT plans by manu-
ally predefining a series of aperture shapes in conjunction with the
beam's eye view (BEV) of the target and organs at risk. Planning pro-
cedure was reported in details in a previous study.4 However,
because the delivery of a SBRT‐VMAT arc takes more than a single
tolerable breath‐hold, we designed a solution to perform a full arc
rotation delivery splitting the arc into short sub‐arcs, for each of
which the delivery time was defined according to the patient prede-
fined breath‐hold period. In the first step, the aperture shape for
each control point within a sub‐arc was determined by the BEV of
the target and the adjacent critical structures, automatically adapting
the leaf edge to the outline of the PTV. Then, the beam weights for
all the control points were optimized by inverse planning based on
the simulated annealing optimization algorithm, so defining the dose‐
rate/monitor units number ratio for each control point. All plans
were optimized with a single full arc. The entire gantry rotation was
described in the optimization process by a sequence of 90 control
points, i.e., one every 4°.
Patient set‐up was checked before every treatment fraction
using the portal images obtained by two perpendicular square
open 10 × 10 cm2 beams (each of which delivers two monitor
units) and their comparison with the corresponding digitally recon-
structed radiographs obtained from the planning CT dataset. Any
deviation greater than 3 mm in the isocenter position was immedi-
ately corrected. The EPID portal image obtained at the end of the
delivery of the VMAT arc in the first treatment fraction was
assumed as the reference image for the subsequent daily γ‐analy-
sis. In other words, the first portal image was used as a surrogate
of EPID transit signals to ensure the highest treatment repro-
ducibility. This means that once the patient setup is corrected
before each treatment fraction, IVD γ‐analysis should supply cor-
rect results if there are no linac or no breath‐control system
failures.
2.B | The SOFTDISO software
SOFTDISO is a commercial system for IVD developed within an Ital-
ian National research project.16 The mathematical aspects of the
dose reconstruction algorithm were deeply explained in a previous
paper.20 The SOFTDISO software is directly interfaced with the
Record & Verify system of the radiotherapy network (Mosaiq, Elekta,
Crawley, UK) and consists of two integrated modules. The first one,
called the “Patient commissioning module”, imports the DICOM files
from the CT scanner and the TPS in order to extract all the needed
radiological and geometrical parameters. The second module, called
the “Test Computation Module”, was developed to obtain the R ratio
between the daily reconstructed dose at isocenter and the planned
isocenter dose. The accuracy of this procedure has been well
reported in literature19 providing a tolerance level of ±5%. The mod-
ule supplies also the γ‐analysis for daily EPID images with respect to
a reference one. The γ‐analysis tests were evaluated in terms of per-
centage of points with γ value less than one (γ%) and in terms of
mean γ values (γmean). Based on previous experience on other
anatomical sites,20,21 a 3% (global)‐3 mm criteria was adopted. Alert
criteria of γ% < 90% and γmean > 0.67 were chosen, to accept only
10% of values above 3%/3 mm and an average discrepancy of 2%/
2 mm. These criteria seems to be a reasonable choice to provide the
detection of significant errors but without a major number of false
positives.
The EPID portal images were automatically imported by the
SOFTDISO software via DICOM protocol and the IVD results were
delivered to a computer screen in quasi real‐time, that is within one
minute from the end of the arc delivery.
2.C | IVD clinical workflow
Electronic portal imaging devices‐based IVD was performed for each
treatment fraction for all enrolled patients, with the aim to steadily
track the treatment reproducibility (mainly, in terms of setup inaccu-
racy and/or breath‐hold failure). If the R ratio and/or the γ‐analysis
values should exceed the tolerance levels, then the medical physicist
examines the IVD chain in order to detect and remove any possible
sources of errors. When the dose discrepancies were unclear, a new
CT scan was required for the patient resimulation and replanning. At
the end of the treatment, as the final act of a multistep quality
assurance process,29 an IVD report is inserted into the patient's
medical chart, providing a record of the actual dose received by indi-
vidual patients.
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3 | RESULTS
A total of 50 transit EPID images, one image for each SBRT‐VMAT
plan, was acquired during the treatment fractions of the 10 patients.
Two images were removed from analysis for an electronic acquisition
failure. Figure 1 shows the R ratios, γ% and γmean histogram values
for all patients; the black bars refer to the eight patients treated with
ABC and the white bars to the two patients treated in free‐breath-
ing. Table 1 reports the overall results for R, γ% and γmean metrics.
For the eight patients treated with ABC spirometer, the results
show a very high level of accuracy in dose delivery, with no dose
discrepancies in any patient (except one test) and a very high inter-
fraction reproducibility. In particular, only one fraction of a patient
of this cohort supplied one of the three metrics out of tolerance
level, with γ% value equal to 78% (while R ratio and γmean values
were equal to 0.95 and 0.56, respectively). Figure 2 shows the
detection of this discrepancy, due a slight variations in the tidal vol-
ume of the patient above the threshold value, leading to a small dis-
placement of the lesion. Excluding from the analysis the only test
providing the aforementioned dose discrepancy, the mean R ratio
resulted equal to 0.994 (range: 0.961–1.042), with 100% of tests
within ±5%. The results for γ‐analysis showed an average values of
γ% and γmean equal to 97.5 (range: 94%–100%) and 0.19 (range:
0.04–0.29), respectively, with 100% of tests within alert criteria for
both metrics.
Larger discrepancies were observed only for the two patients
treated without the ABC, and where all described by the γ% tests
outside the alert criteria. In fact, for these two patients the R ratios
were in the range of 0.95–0.99 for all the tests, that is, no dose dis-
crepancies outside tolerance level were observed at the isocenter
point. Similarly, the γmean tests provided values smaller than 0.67
(range: 0.38–0.66). However, the 2D γ‐analysis clearly reported large
off‐axis deviations in γ%, which dropped below 90% for all the tests.
Figure 3 shows an example of poor treatment reproducibility for one
of these patients; this graphical result could be justified by a dose
blurring effect due to the residual respiration motion of the lesion
across the beam central axis, mainly in the cranio‐caudal direction.
4 | DISCUSSION
Stereotactic body radiotherapy has become a critical component of
the cancer treatment process, demonstrating a great efficacy in
many disease sites. This complex and technology‐driven clinical pro-
cedure requires the highest level of attention for safe application. In
the last years, serious errors have occurred leading to severe
patients’ complications, including a linac calibration error in Florida
(affecting 77 patients in 2004–2005), wrong measurements of out-
put factors both in France (affecting 145 patients in 2006–2007)
and in Missouri (affecting 152 patients in 2004–2009,30 and the
well‐known lethal over‐irradiation of a patient in Scotland.31 A
review of the Nuclear Regulatory Commission Radiation Event
Report Notification database reported other 13 stereotactic‐related
events in the period 2004–2010, mainly due to wrong targeting and
isocenter setting and to errors in dose planning.32
The integration in SBRT process of advanced techniques as
VMAT and gating/breath‐hold systems for organ‐motion control has
the potential to further increase the accuracy and outcomes of SBRT
F I G 1 . Distribution of (a) R ratios, (b) γ%, and (c) γmean values for the 10 patients. Black bars indicate the tests for the patients treated with
the ABC system; white bars indicate the tests for the two patients treated in free‐breathing.
TAB L E 1 Overall results for R, γ% and γmean metrics.
Patients treated with
ABC (n = 8)
Patients treated without
ABC (n = 2)
R ratio γ% γmean R ratio γ% γmean
Mean
values
0.993 96.9 0.21 0.972 80.1 0.52
Range 0.95–
1.04
78–
100
0.04–
0.56
0.95–
0.99
73–
87
0.38–
0.66
% within
tolerance
level
100 98 100 100 0 100
40 | CILLA ET AL.
treatment. On the other hand, an even higher level of confidence of
the entire treatment delivery process is required, because each new
implemented technique can in turn become a new source of error.
For example, an error in respiratory management parameters for a
patient receiving a SBRT lung treatment was documented, in which
the gating phase and breathing cycle parameters were inadvertently
changed during the course of the treatment.33 Following the occur-
rence of the aforementioned incidents, a number of guidance docu-
ments for the implementation and routine maintenance of high‐
quality stereotactic programs have been published.34,35 All these
reports suggested the implementation of IVD in clinical routine, as
the last hedge able to intercept machine and patient‐specific errors
during the dose delivery. This suggestion should be mandatory when
new advanced technologies and treatments are implemented in clini-
cal routine and potential limitations still have to be assessed. In this
case, since unexpected and unknown errors may occur, a robust IVD
program should be able to trace deviations between planned and
actually delivered doses that could be missed by pretreatment verifi-
cation.9
We reported our initial experience for clinical application of IVD
for complex SBRT‐VMAT treatments of lung metastases using a
breath‐hold system for organ motion control. At present, our method
supplies the daily dose reconstruction only along the beam axis at
isocenter point, providing a robust warning for major dose variations
(i.e., linac or other technical failures). Treatment reproducibility,
instead, is performed by γ‐analysis comparison between daily portal
images. We demonstrated that this procedure, even if it is not a true
2D dosimetric comparison, can trace back the causes of transit signal
changes, allowing a prompt action to remove any clinically relevant
dose discrepancies before compromising the aim of patient curative
treatment.21 The small number of patients enrolled in the present
study does not allow a statistically significant comparison between
the results obtained for the patients treated with and without ABC
system. However, this was not the aim of this paper that was
(a) (b) (c) (d) (e) (f)
F I G 2 . Detection of a poor treatment reproducibility in a patient treated using the ABC spirometer. From left to right, (a) the CT scan at
isocenter level; (b) the reference integrated EPID image; (c–f) the IVD tests with a relevant discrepancy provided by γ‐analysis in figure (d).
(a) (b) (c) (d) (e) (f)
F I G 3 . Detection of dose discrepancies in a patient treated in free‐breathing using IVD procedure. From left to right, (a) the CT scan at
isocenter level; (b) the reference integrated EPID image; (c–f) the IVD tests showing a poor treatment reproducibility probably due to the
residual tumor motion and a blurring dose effect.
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instead focused on the ability of our IVD procedure to identify treat-
ment‐related dose discrepancies also during SBRT‐VMAT delivery.
This aim has been well‐illustrated by two examples. First, major dis-
crepancies in treatment reproducibility were found for the two
patients treated without ABC. In particular, we want to highlight that
the observed discrepancies for these two patients were detected
only by γ‐analysis of the 2D portal images. This finding was mainly
due to the fact that in SBRT‐VMAT treatments of lung metastases,
the isocenter is always located at the center of the lesion so that
the beam central axis is always crossed by the tumor during the
residual respiratory motion, preventing a detectable reduction of the
radiological path and then relevant isocenter dose discrepancies. It
must however be emphasized that, in the present clinical setting, the
isocenter point is always located in the center of the tumor, in a
homogenous dose region, thus representing a relevant point for dose
verification purposes and providing, for example, a major warning for
technical failure (linac output variations or MLC failures). In other
anatomical sites as head‐neck or breast cancer, the isocenter point is
often located in regions with high‐gradient dose or in very low dose
regions, producing unreliable dose assessments. As shown in Fig. 3,
the lack of reproducibility of the treatment is mainly located at the
periphery of the lesion, suggesting a probable dose blurring effect
due to the residual tumor motion. The impact of these discrepancies
for the target volume remains difficult to quantify. In our anatomy‐
based VMAT optimization strategy, the field shape always conform
to the PTV outline, and this choice should avoid both target missing
and possible interplay effect. Only a DVH‐analysis based on 3D IVD
would allow a quantitative assessment of the clinical relevance of
observed deviations.36,37 Secondly, as shown in Fig. 2, a patient trea-
ted with ABC failed to fulfill the γ% criterion, with a fall of γ% down
to 78%. Although still within tolerance levels, this test supplied also
the worst result for the R ratio (R = 0.95) and for the γmean metric
(γmean = 0.56). A careful inspection of possible causes highlighted
small variations in held volume above the threshold value that may
result in a variation of the tumor position. This effect is probably
due to the delay between the ABC activation and the balloon valve
closing, depending on the flow rate when the threshold volume is
reached, with high flow rates causing an overshoot of the threshold
value.
Our back‐projection algorithm for IVD was developed by means
of correlation functions between isocenter dose and EPID signals
that were obtained using homogeneous phantoms.10,13,18 Although
our model takes into account the amount of scatter radiation due to
the distance of the patient from the Epid, it does not directly model
the scatter contribution coming from low density tissues surrounding
the tumor. Anyway, the goodness of our results for the isocenter
dose reconstruction, reporting an agreement with planned dose
within 5% in all tests, suggests that the loss of electronic equilibrium,
which should result in an effectively tumor lower dose, can be con-
sidered negligible for the purposes of IVD in this clinical setting. In
an our previous study38 we used an heterogeneous phantom to ver-
ify the agreement between the doses calculated with pencil beam
algorithms, the in‐vivo dose and the doses measured along the beam
central axis (with a small ionization chamber), which crossed a target
in water equivalent material surrounded by cork equivalent to typical
lung density. For dynamic conformal arc technique the results
reported an agreement within 2% (with a tendency to an overesti-
mation of our algorithm). This result was obtained if the conformal
arc irradiation of the lung target included a thickness of lateral low
density cork medium less than 1 cm. This condition, typical in the
setting of lung SBRT where margins around the target are less than
1 cm, assured that the effect of the lateral disequilibrium is negligible
for the in vivo dose reconstruction at isocenter (e.g., the center of
the lung lesion).
It must be underlined that all the detected dose discrepancies
would not have been detected by means of pretreatment dose veri-
fication. In our clinical workflow for SBRT quality assurance, pre-
treatment dosimetric verification is performed for all plans using a
stringent local 3%‐3 mm γ criterion with the aim to detect any
sources of errors related to treatment planning system and/or to the
ability of linac to deliver the planned dose. Only plans resulting in a
γ% pass‐rate higher than 95% are accepted. Then, epid‐based IVD is
performed to daily monitor any errors that may occur during the
treatment fractions. A global 3%‐3 mm γ criterion was chosen for
the IVD tests to avoid an excess of high false‐positive events that
could frequently discontinue the treatment to trace‐back small dose
discrepancies without any clinical impact. This way, the main goal of
our IVD approach is to efficiently detect the dose discrepancies that
are potentially clinically significant, rather than achieve the highest
accuracy in the dose reconstruction. The choice of three simultane-
ous pass/fail criteria should reduce the risk of missing major clinically
relevant dose discrepancies.
In particular, our overall results confirm the correctness of the
adopted tolerance/action levels of 5% for R ratios, and >90% of γ%
pass‐rate and <0.67 for γmean when using a 3%(global)/3 mm criteria.
For the eight patients that underwent ABC treatment, 100% of the
R ratio, γmean and γ% tests resulted within their respective alert crite-
ria, excluding one test for which the reasons for the disagreement
have been understood. The adopted tolerance levels clearly demon-
strated the power to highlight even small discrepancies in the treat-
ment reproducibility. In particular, the γ% pass‐rate metric resulted in
the best discriminator for the detection of discrepancies in the treat-
ment reproducibility. However, it must be underlined that all tests
for patients treated with the ABC system provided γmean values less
than 0.33 (excluding the aforementioned single test showing dose
discrepancy). This means that the reproducibility of our breath‐hold
SBRT‐VMAT treatments could be tested at a level of average dis-
crepancies of 1%/1 mm, suggesting the use of lower criteria for γmean
in this clinical setting (e.g., γmean<0.33). In other words, the average
γmean value of 0.19 (range: 0.04–0.29) found in this clinical setting
means that the average dose differences among the various treat-
ment fractions is less than 1%, indicating a very high treatment
reproducibility for patients treated with the ABC system, and allow-
ing the use of the stringent γmean<0.33 criterion. The values for the
alert criteria used in the clinical application for the different γ‐evalua-
tion indicators deserve further deeper investigations. The recent
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recommendations of the AAPM Task Group No. 21839 highlighted
that discrepancy tolerance limits are neither well‐defined nor consis-
tently applied across Centers in patient‐specific IMRT quality assur-
ance. In general, the definition of tolerance and action levels is much
more challenging for in vivo dosimetry purposes, mainly depending
on the ability of the IVD equipment to detect errors requiring cor-
rections. In particular, the dose delivery process performance outside
action levels should be considered unacceptable and demanding
actions to promptly correct. Following our past experience,21 the
action levels were set equal to the tolerance levels, so as to investi-
gate any test outside the tolerance levels and to trace back possible
errors in (a) linac or other equipment failure, (b) patient set‐up, (c)
breath‐hold control device failure, and (d) patient's morphological
changes. We are currently performing a comprehensive sensitivity
analysis to ensure the best detectability for several types of errors in
the various clinical settings, including SBRT.
An ideal IVD system should produce results instantaneously,
during the beam delivery, in order to detect gross error as they
occur, e.g., before the delivery of the whole dose to the patient. In
the past years, we explored this feasibility for dynamic conformal
arc therapy.38 Our aim was to monitor the treatment reproducibil-
ity in real time using a transmitted current signal sampled at inter-
val time of 110 ms supplied by a small ionization chamber located
at portal level. This strategy was then successfully applied to moni-
tor the tumor position reproducibility during the treatment of lung
cancer patients treated with 3D‐conformal therapy and using the
ABC spirometer.40 However, the transition to an Epid‐based IVD
for online treatment verification poses serious technological issues
still today that prevent its manageable clinical implementation. Our
previous research41 reported the feasibility to obtain the “real‐time”
isocenter dose in dynamic conformal arc therapy using the signal
supplied by an EPID cine acquisition mode every 1.66 s during the
treatment. A more complex experience of real‐time IVD using Epids
was reported by Woodruff et al.,42 who demonstrated the feasibil-
ity of this approach in a clinical setting for head‐neck and pelvic
IMRT and VMAT treatments. The authors developed a real‐time
IVD method based on the comparison between measured and pre-
dicted portal images, showing the feasibility to catch large delivery
errors. A research on real‐time Epid‐based 3D dose reconstruction,
also using DVH‐analysis, is ongoing at the Netherland Cancer Insti-
tute (NKI), where the authors have successfully combined their
online dose verification system with a linac halting mechanism in
cases of major discrepancies.43 Obviously, a true real‐time IVD
approach is even more stringent for single fraction radiosurgical
treatments.
5 | CONLUSIONS
In conclusion, our preliminary results suggested that our IVD method
provide a fast and accurate procedure in clinical routine for verifying
delivered dose as well as for detecting dose discrepancies in lung
SBRT treatments. IVD has been shown to identify dose
discrepancies that would have been missed with other quality assur-
ance methods. The use of ABC in lung SBRT translates in very high
reproducibility treatments.
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